Skip to main content
It looks like you're using Internet Explorer 11 or older. This website works best with modern browsers such as the latest versions of Chrome, Firefox, Safari, and Edge. If you continue with this browser, you may see unexpected results.

University Library, University of Illinois at Urbana-Champaign

COVID-19 Vaccines

Information and evidence about COVID-19 vaccine efficacy and safety

PFIZER-BIONTACH COVID-19 VACCINE

Safety Data Summary

  • In clinical trials, reactogenicity symptoms (side effects that happen within 7 days of getting vaccinated) were common but were mostly mild to moderate.
  • Side effects (such as fever, chills, tiredness, and headache) throughout the body were more common after the second dose of the vaccine.
  • Most side effects were mild to moderate. However, a small number of people had severe side effects—defined as side effects affecting a person’s ability to do daily activities.
  • Although few people in the clinical trials went to the hospital or died, data suggest that people who got the Pfizer-BioNTech vaccine were less likely to have these more serious outcomes compared to people who got the saline placebo.
  • CDC will continue to provide updates as we learn more about the safety of the Pfizer-BioNTech vaccine in real-world conditions.

SOURCE: CDC - ttps://www.cdc.gov/coronavirus/2019-ncov/vaccines/different-vaccines/Pfizer-BioNTech.html (April 15, 2021)

Clinical Trial Demographic Information

Clinical trials for the Pfizer-BioNTech vaccine included people from the following racial and ethnic, age, and sex categories:

  • 81.9% White
  • 9.8% African American
  • 4.4% Asian
  • <3% other races/ethnicities
  • <1% Native Hawaiian or Other Pacific Islander
  • <1% American Indian or Alaska Native

Ethnicity

  • 2% Not Hispanic or Latino
  • 2% Hispanic of Latino
  • <1% Not Reported

Age and sex breakdown:

  • 50.6% male
  • 49.4% female
  • 21.4% 65 years and older​

Age

  • 9% 16 to 55 years
  • 8% 55 years and older
  • 4% 65 years and older​
  • 3% 75 years and older

The most frequent underlying medical conditions were obesity (35.1%), diabetes (8.4%), and pulmonary disease (7.8%).

SOURCE: CDC - ttps://www.cdc.gov/coronavirus/2019-ncov/vaccines/different-vaccines/Pfizer-BioNTech.html (April 15, 2021)